Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers

HER2-positive (HER2+) breast cancer is defined by HER2 oncogene amplification on chromosome 17q12 and accounts for 15–20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. However, more than 50...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchukulla, Ratnakar Reddy, Hwang, Injeoung, Park, Sang Won, Moon, Sojeong, Kim, Suhn Hyung, Kim, Sumin, Chung, Hwan Won, Ji, Mi-Jung, Park, Hyun-Mee, Kong, Gu, Hur, Wooyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506414/
https://www.ncbi.nlm.nih.gov/pubmed/36145262
http://dx.doi.org/10.3390/ph15091041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506414/
https://www.ncbi.nlm.nih.gov/pubmed/36145262
http://dx.doi.org/10.3390/ph15091041

Ejemplares similares